Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2021
October 13 - 15, 2021; Virtual
October 13 - 15, 2021Virtual
ECTRIMS 2021Serum Neurofilament Light Level May Predict MS ProgressionHigh serum levels of neurofilament light are associated with an increased risk for disease progression at 2 years. Clinical, MRI, and OCT measures are not associated with this risk, however.
ECTRIMS 2021Ublituximab Improves Functional MS Score: New ULTIMATE AnalysisThe new anti-CD20 monoclonal antibody showed significant improvement in the multiple sclerosis functional composite (MSFC) score, a measure of disability, compared with teriflunomide.
Masitinib Impresses in 'Nonactive' Progressive MSThe drug, with a completely new mechanism of action for multiple sclerosis, slowed disability in nonactive primary and secondary
progressive forms of the disease, where there is no current treatment.
Medscape Medical News, Sep 13, 2020
High Plasma GFAP Level Predicts Disability in Progressive MSA high level of glial fibrillary acidic protein (GFAP) in the blood may predict worsening disability in patients with secondary
progressive multiple sclerosis (MS), according to investigators.
Medscape Medical News, Sep 14, 2020
Lower Rituximab Dose as Effective, Safer in MSFurther data suggest that a lower dose of rituximab may offer similar effectiveness with a better safety profile than a higher
dose commonly used.
